Guwahati Mail

DelveInsight’s, “Tuberculosis Pipeline Insight, 2022,” report provides comprehensive insights about 35+ companies and 35+ pipeline drugs in Tuberculosis pipeline landscape.

Tuberculosis Pipeline landscape is provided which includes the disease overview and Tuberculosis treatment guidelines. The assessment part of the Tuberculosis pipeline report embraces, in depth Tuberculosis commercial assessment and clinical assessment of the pipeline products under development. In the Tuberculosis Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Tuberculosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Key takeaways from the Tuberculosis Pipeline Report

• DelveInsight’s Tuberculosis Pipeline analysis depicts a robust space with 35+ active players working to develop 35+ pipeline therapies for Tuberculosis treatment.
• Leading Tuberculosis companies include Serum Institute of India Pvt. Ltd., AnHui Longcom Biologic Pharmacy, Biofabri, S.L, Immunitor LLC, Shanghai Jiatan Pharmatech, GlaxoSmithKline, Archivel Farma S.L., LegoChem Biosciences, Quratis Inc, Qurient Co., Sequella, Inc., Vaxil Biotherapeutics, Tianjin CanSino Biotechnology, Global Alliance for TB Drug Development, BioNtech, TaBriX, Moderna, GC Biopharma, AJ Vaccines, Vaxxit Srl, Vaxil Bio Therapeutics, Vaxine Pty Ltd,  TVAX Biomedical, Theravectys SA, Tydockpharma, PDS Biotechnology, PAI lifesciences, EpiVax, Inc., GlobeImmune Inc., Zymergen, Jiangsu Recbio Technology, and others are evaluating their lead assets to improve the Tuberculosis treatment landscape.
• Promising Tuberculosis pipeline therapies in various stages of development include VPM1002, MTBVAC, ESAT-CFP10, V7, WX-081, GSK 692342, GSK3036656, RUTI, LCB01-0371, ID 93, AERAS-404, Telacebec, Sutezolid, OPC-167832, Tuberculosis Vaccine, TBA 7371, TBAJ-876, SPR720, BNT164, GSK2556286, GC3107A, MTbuVax, PDS0201, GI19000, REC 607, and others.
• Telacebec (Q203) is one of the first candidates getting close to forming new universal regimen. Telacebec (Q203) is an orally active small molecule drug candidate that blocks Mycobacterium tuberculosis growth by inhibiting cytochrome bc1 complex, leading to the depletion of adenosine triphosphate (ATP) synthesis of M. tuberculosis. Telacebec (Q203) shows good synergy with bedaquiline in murine chronic infection model, indicating promising potential for new drug regimen. The drug is currently in phase 2 stage of development.
• VPM1002 facilitates mycobacterial antigens being released into the cytosol while also triggering autophagy, inflammasome activation, and apoptosis, because of antigens and bacterial DNA being released into the cytosol of the host cell due to Listeriolysin O expression in this vaccine. Mycobacterial antigen accessing the cytosol also improves antigen presentation. The ability for mycobacterial antigens to reach the cytosol is due to this vaccine being engineered to secrete Hly which perforates phagosomal membranes. Currently, it is in phase III stage of development for the treatment of Tuberculosis.

Request a sample and discover the recent advances in Tuberculosis @ Tuberculosis Pipeline Outlook

The Tuberculosis Pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Tuberculosis, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Tuberculosis Pipeline Landscape.

Tuberculosis Overview

Tuberculosis (TB) is a bacterial infection spread through inhaling tiny droplets from the coughs or sneezes of an infected person. Tuberculosis (TB) is caused by a bacterium called Mycobacterium tuberculosis. The bacteria usually attack the lungs, but TB bacteria can attack any part of the body such as the kidney, spine, and brain. Not everyone infected with TB bacteria becomes sick. As a result, two TB-related conditions exist: latent TB infection (LTBI) and TB disease.

Recent Breakthroughs and Developments in the Tuberculosis Treatment Landscape

• In January 2022, GlaxoSmithKline’s GSK-3036656 saw its Phase Transition Success Rate (PTSR) climb seven points to 55% after its Phase II pulmonary tuberculosis trial was completed.
• In March 2022, Bharat Biotech announced a partnership with Biofabri, a Spanish biopharmaceutical company, to develop, manufacture and market a new tuberculosis vaccine ‘MTBVAC’. The partnership guarantee the supply of TB vaccines in more than 70 countries, especially in Southeast Asia and sub-Saharan Africa.
• In April 2022, Moderna and the nonprofit scientific research organization IAVI entered into a new collaboration to employ mRNA technology to meet the challenge of a range of global health threats, including HIV/AIDS, tuberculosis (TB), and antimicrobial-resistant enteric infections, and COVID-19.
• TaBriX and The University of Manchester are working in collaboration with TB Alliance to assess how effective TB drug candidates are alone and in combination with the current standard of care. TaBriX is a new spin-out company from The University of Manchester (UoM) with the mission to create novel anti-virulence drugs to fight difficult-to-treat infections.
• Zymergen has demonstrated early results from its infectious disease program, supported by a grant from the Bill & Melinda Gates Foundation, which discovered hundreds of potential novel hits against malaria, tuberculosis, and COVID-19 targets.

Tuberculosis Emerging Drugs

• Telacebec (Q203): Qurient Co
• VPM1002: Serum Institute of India

Tuberculosis Pipeline Analysis Report

• The report provides detailed insights about emerging therapies for the treatment of Tuberculosis and the aggregate therapies developed by major pharma companies.
• It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Tuberculosis Treatment.
• It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• The Tuberculosis Pipeline Report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Anthrax market.

The Tuberculosis Pipeline Report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Key facts of Tuberculosis Pipeline Landscape

• In 2020, Tuberculosisclaimed the lives of 1.5 million persons worldwide (including 214 000 people with HIV). Following COVID-19 (behind HIV/AIDS), Tuberculosis is the second infectious killer in the world and the 13th largest cause of death overall.
• Globally, 10 million cases of tuberculosis (TB) are anticipated in 2020. There are 1.1 million kids, 3.3 million women, and 5.6 million males. Tuberculosisexists in all nations and among all age groups. However, Tuberculosiscan be treated and avoided.
• Around the world, 1.1 million kids contracted Tuberculosisin 2020. It can be challenging to diagnose and treat child and adolescent Tuberculosis, which is frequently ignored by healthcare professionals.

Scope of the Tuberculosis Pipeline Report

• Coverage: Global
• Tuberculosis Pipeline Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Tuberculosis Pipeline Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Tuberculosis Pipeline Therapeutics Assessment By Route of Administration: Oral, Parenteral, Subcutaneous, Topical, Intravenous
• Tuberculosis Pipeline Therapeutics Assessment By Molecule Type: Gene therapy, Small molecule, Polymers, Peptides, Monoclonal antibodies
• Tuberculosis Pipeline Therapeutics Assessment By Mechanism of Action: Bacterial growth inhibitors, Electron transport complex III inhibitors, Leukotriene inhibitors, Immunostimulants, Adenosine triphosphatase inhibitors, DprE1 protein inhibitors, Interferon type I stimulants; T lymphocyte stimulants.
• Key Tuberculosis Companies: Serum Institute of India Pvt. Ltd., AnHui Longcom Biologic Pharmacy, Biofabri, S.L, Immunitor LLC, Shanghai Jiatan Pharmatech, GlaxoSmithKline, Archivel Farma S.L., LegoChem Biosciences, Quratis Inc, Qurient Co., Sequella, Inc., Vaxil Biotherapeutics, Tianjin CanSino Biotechnology, Global Alliance for TB Drug Development, BioNtech, TaBriX, Moderna, GC Biopharma, AJ Vaccines, Vaxxit Srl, Vaxil Bio Therapeutics, Vaxine Pty Ltd,  TVAX Biomedical, Theravectys SA, Tydockpharma, PDS Biotechnology, PAI lifesciences, EpiVax, Inc., GlobeImmune Inc., Zymergen, Jiangsu Recbio Technology, and others.
• Key Tuberculosis Pipeline Therapies: VPM1002, MTBVAC, ESAT-CFP10, V7, WX-081, GSK 692342, GSK3036656, RUTI, LCB01-0371, ID 93, AERAS-404, Telacebec, Sutezolid, OPC-167832, Tuberculosis Vaccine, TBA 7371, TBAJ-876, SPR720, BNT164, GSK2556286, GC3107A, MTbuVax, PDS0201, GI19000, REC 607 and others.

Dive deep into rich insights for Tuberculosis drugs, visit @ Tuberculosis Drugs

Table of Content

1. Introduction
2. Executive Summary
3. Tuberculosis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Phase III)
7. Telacebec (Q203): Qurient Co
8. Mid Stage Products (Phase II) 
9. WX-081: Shanghai Jiatan Pharmatech
10. Early Stage Products (Phase I/II)
11. OPC-167832: Otsuka Pharmaceutical
12. Inactive Products
13. Tuberculosis Key Companies
14. Tuberculosis Key Products
15. Tuberculosis- Unmet Needs
16. Tuberculosis- Market Drivers and Barriers
17. Tuberculosis- Future Perspectives and Conclusion
18. Tuberculosis Analyst Views
19. Tuberculosis Key Companies
20. Appendix

For further information on the Tuberculosis Pipeline therapeutics, reach out @ Tuberculosis Pipeline Landscape

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/